CDA Diefenbach Medpace Protocol ID ME-522-001 titled: A Phase 1 Open-label Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies After Failure of Prior Standard Therapies



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.